EVALUATION OF VP-16-213 IN MALIGNANT-LYMPHOMA AND MELANOMA

  • 1 January 1978
    • journal article
    • research article
    • Vol. 62  (5) , 801-803
Abstract
Phase II studies utilizing VP-16-213 [4''-demethylepipodophyllotoxin-.beta.-D-ethylidene glucopyranoside] in the treatment of 56 patients with malignant lymphoma and 29 patients with malignant melanoma were done by the Southwest Oncology Group. All patients received extensive prior therapy. The initial dose of VP-16-213 administered was 45 mg/m2 by i.v. infusion over 30-60 min on days 1-5 every 3 wk but, because of severe myelosuppression in the lymphoma group, the dose was subsequently reduced to 35 mg/m2. Only 3 partial regressions lasting 6, 2 and 1+ mo. were noted in 17 patients with Hodgkin''s disease. No favorable responses were noted in 35 patients with non-Hodgkin''s lymphoma including 16 with the diffuse histiocytic type. No responses were noted in patients with melanoma. The major toxic effect was myelosuppression. VP-16-213 appears to lack significant effectiveness in these previously treated diseases.

This publication has 1 reference indexed in Scilit: